Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials

Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2023) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, (Accepted for Publication)

[img] Text
311526.pdf - Accepted Version
Restricted to Repository staff only

361kB

Item Type:Articles
Additional Information:SR receives support through an unrestricted grant from Roche Diagnostics. NNL and MCP are supported by a British Heart Foundation Centre of Research Excellence Award (BHF RE/18/6/34217).
Status:Accepted for Publication
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mark, Professor Patrick and Lees, Jennifer and Venugopal, Dr Balaji and Rankin, Dr Stephen and Petrie, Professor Mark and Jones, Professor Robert and Lang, Professor Ninian and Elyan, Dr Benjamin
Authors: Lang, N., Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B., Lees, J., Petrie, M., and Lang, N.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:JACC: CardioOncology
Publisher:Elsevier
ISSN:2666-0873

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303944BHF Centre of ExcellenceColin BerryBritish Heart Foundation (BHF)RE/18/6/34217SCMH - Cardiovascular & Metabolic Health